Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia

We describe outcomes after HSCT for congenital amegakaryocytic thrombocytopenia (CAMT; n=86) from 2000 to 2018.Study Design: We conducted an analysis of data collected by the Center for International Blood and Marrow Transplant Research on patients with CAMT receiving therapeutic allogeneic HSCT.

Source: Biology of Blood and Marrow Transplantation - October 17, 2021 Category: Hematology Authors: Maria Cancio, Kyle Hebert, Soyoung Kim, Mahmoud Aljurf, Timothy Olson, Eric Anderson, Lauri Burroughs, Anant Vatsayan, Kasiani Myers, Hasan Hashem, Rabi Hanna, Biljana Horn, Tim Prestidge, Jaap-Jan Boelens, Farid Boulad, Mary Eapen Source Type: research